RecruitingNCT06223607
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
Sponsor
Methodist Health System
Enrollment
300 participants
Start Date
Aug 22, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- ≥ 18 years
- PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
- Thrombocytopenia defined as platelet count <100 x103 /µL on at least one occasion prior to PCI
- At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
Exclusion Criteria2
- Death within 48 hours post-PCI
- DAPT prior to cardiac catheterization
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06223607